- Market Capitalization, $K 1,202,574
- Shares Outstanding, K 114,859
- Annual Sales, $ 251,250 K
- Annual Income, $ 75,410 K
- 60-Month Beta 1.54
- Price/Sales 4.82
- Price/Cash Flow 16.10
- Price/Book 4.24
|Period||Period Low||Period High||Performance|
| || |
+0.08 (+0.78%)since 05/24/19
| || |
-0.78 (-6.98%)since 03/22/19
| || |
-5.67 (-35.31%)since 06/22/18
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics Incorporated, Mobile TeleSystems PJSC, Healthcare Services...
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept"...
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corcept Therapeutics Incorporated (NASDAQ: CORT) from August 2, 2017 through February 5, 2019, inclusive (the...
Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm:
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT)...
Corcept (CORT) delivered earnings and revenue surprises of 11.11% and -3.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
|S&P Small-Cap Ishares Core ETF|
|Russell 2000 Ishares ETF|
|S&P Small-Cap 600 Growth Ishares ETF|
|Dynamic Pharmaceuticals Invesco ETF|
|Russell 2000 Growth Ishares ETF|
|Pacer US Small Cap Cash Cows 100 ETF|
|S&P 1500 Momentum Tilt ETF SPDR|
|Db-Xt Russell 2000 Comp Factor ETF|
|S&P Smallcap 600 Pure Growth Invesco ETF|
|S&P Smallcap 600 SPDR|